CT1812 slows cognitive decline in proof-of-concept Alzheimer's trial
CT1812 was shown to slow the decline of cognitive function in adults with Alzheimer’s disease in a proof-of-concept clinical trial.| Alzheimer's News Today
CT1812 was shown to slow the decline of cognitive function in adults with Alzheimer’s disease in a proof-of-concept clinical trial.| Alzheimer's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
